Elranatamab as Maintenance Therapy
Phase II Study of Elranatamab as Maintenance Therapy Post Ciltacabtagene-autoleucel(Cilta-cel) in Patients With Clinical High Risk Relapsed Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 39 patients (estimated)
- Sponsors
- Moffitt Cancer Center
- Collaborators
- Pfizer
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), High Risk, Maintenance, Post-CAR T
- Trial Type
- Treatment
- Last Update
- 3 weeks ago
- SparkCures ID
- 2110
- NCT Identifier
- NCT06947083
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.